Modified docetaxel and cisplatin in combination with capecitabine (DCX) as a first-line treatment in HER2- negative advanced gastric cancer

Basit Öğe Kaydı
dc.contributor.authorBilici, Ahmet
dc.contributor.authorSelçukbiricik, Fatih
dc.contributor.authorDemir, Nazan
dc.contributor.authorÖven Ustaalioğlu, Bala Başak
dc.contributor.authorDikilitaş, Mustafa
dc.contributor.authorYıldız, Özcan
dc.date.accessioned10.07.201910:49:13
dc.date.accessioned2019-07-10T19:36:24Z
dc.date.available10.07.201910:49:14
dc.date.available2019-07-10T19:36:24Z
dc.date.issued2014
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı
dc.description.abstractBackground: Docetaxel and cisplatin in combination with fluorouracil (DCF) regimen is accepted to be one of the standard regimens in the treatment of advanced gastric cancer. However, substantial toxicity has limited its use in daily clinical practice. Therefore, modification of DCF regimens, including introduction of capecitabine has been investigated to improve the safety profiles. In the present study, the efficacy and toxicity of a regimen with a modified dose of docetaxel and cisplatin in combination with oral capecitabine (DCX) was evaluated in untreated patients with HER2-negative advanced gastric cancer. Materials and Methods: Fifty-four patients with HER2-negative locally advanced or metastatic gastric cancer were included in this cohort. Patients received docetaxel 60mg/m2 plus cisplatin 60mg/m2 (day 1) combined with capecitabine 1650mg/m2 (days 1-14) every 3 weeks. Treatment response, survival, and toxicity were retrospectively analyzed. Results: The median age was 54 years (range: 24-76). The majority of patients (70%) had metastatic disease, while 11 patients (21%) had recurrent disease and underwent curative gastrectomy, and 5 patients (9%) had locally advanced disease (LAD). The median number of DCX cycles was 4. There were 28 partial responses and 11 complete responses, with an overall response rate of 72%. Curative surgery could be performed in four patients among five with LAD. At the median follow-up of 10 months, the median progression-free survival (PFS) and overall survival (OS) of the entire cohort of patients were 7.4 and 12.1 months, respectively. Dose modification was done in 12 patients due to toxicity in 8 and noncompliance in 4 patients. The most common hematological toxicity was neutropenia, which occurred at grade 3-4 intensity in 10 of 54 patients (27.7%). Febrile neutropenia was diagnosed only in two cases. Conclusions: DCX regimen offers prominent anti-tumor activity and considered to be effective firstline treatment with manageable toxicity for patients with HER2-negative advanced gastric cancer.
dc.identifier.citationBilici, A., Selçukbiricik, F., Demir, N., Öven Ustaalioğlu, B. B., Dikilitaş, M. ve Yıldız, Ö. (2014). Modified docetaxel and cisplatin in combination with capecitabine (DCX) as a first-line treatment in HER2- negative advanced gastric cancer. Asian Pacific Journal of Cancer Prevention, 15(20), 8661-8666. https://dx.doi.org/10.7314/APJCP.2014.15.20.8661
dc.identifier.doi10.7314/APJCP.2014.15.20.8661
dc.identifier.endpage8666
dc.identifier.issn1513-7368
dc.identifier.issue20
dc.identifier.scopusqualityQ2
dc.identifier.startpage8661
dc.identifier.urihttps://hdl.handle.net/20.500.12511/1150
dc.identifier.urihttps://dx.doi.org/10.7314/APJCP.2014.15.20.8661
dc.identifier.volume15
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherAsian Pacific Organization for Cancer Prevention
dc.relation.ispartofAsian Pacific Journal of Cancer Preventionen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectAdvanced Gastric Cancer
dc.subjectCapecitabine
dc.subjectCisplatin
dc.subjectDocetaxel
dc.subjectFirst-Line Chemotherapy
dc.subjectHER2-Negative
dc.titleModified docetaxel and cisplatin in combination with capecitabine (DCX) as a first-line treatment in HER2- negative advanced gastric cancer
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
bilici-ali(2014).pdf
Boyut:
335.28 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu